Skip to main content
. 2021 Mar 25;11:651921. doi: 10.3389/fonc.2021.651921

Figure 3.

Figure 3

SLC39A8 was down expression and positively associated with tumor progression and worse prognosis in ccRCC patients. (A) ONCOMINE database analysis showed that the mRNA expression levels of SLC39A8 were down-regulated in ccRCC in statistics by Beroukhim et al. (45) and Jones et al. (46), but similar in two studies of Lenburg et al. (47) and Gumz et al. (48). In addition, data analysis based on TCGA showed that with the progression of tumor, the expression of SLC39A8 decreased progressively. (B) Survival curve analysis determined that low SLC39A8 expression exhibits a shorter OS and DSS time in progressive ccRCC patients (T3 + T4, Stage III + IV, Grade 3 + 4). OS, overall survival; DSS, disease specific survival. *P <0.05, **P <0.01, ***P <0.001, ****P <0.0001.